Thank you for sharing!

Your article was successfully shared with the contacts you provided.

In early 2003 Jeffrey Kindler, Pfizer Inc.’s vice-chairman and general counsel, had a big problem — and what seemed, on first glance, a baffling solution. Pfizer was facing what Kindler calls “the most significant patent case” in the company’s century-and-a-half history — a challenge to the key patents on its blockbuster cholesterol-busting drug, Lipitor. Estimated to account for about 30 percent of Pfizer’s profits, Lipitor took in $12.2 billion in 2005. And while it was Pfizer that had brought the case — a patent infringement suit to keep India-based Ranbaxy Laboratories Ltd. from marketing generic Lipitor — it became clear early on that Pfizer would be the one playing defense, with Ranbaxy throwing practically every patent challenge in the book at it.

This content has been archived. It is available exclusively through our partner LexisNexis®.

To view this content, please continue to Lexis Advance®.

Not a Lexis Advance® Subscriber? Subscribe Now

Why am I seeing this?

LexisNexis® is now the exclusive third party online distributor of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® customers will be able to access and use ALM's content by subscribing to the LexisNexis® services via Lexis Advance®. This includes content from the National Law Journal®, The American Lawyer®, Law Technology News®, The New York Law Journal® and Corporate Counsel®, as well as ALM's other newspapers, directories, legal treatises, published and unpublished court opinions, and other sources of legal information.

ALM's content plays a significant role in your work and research, and now through this alliance LexisNexis® will bring you access to an even more comprehensive collection of legal content.

For questions call 1-877-256-2472 or contact us at customercare@alm.com


ALM Legal Publication Newsletters

Sign Up Today and Never Miss Another Story.

As part of your digital membership, you can sign up for an unlimited number of a wide range of complimentary newsletters. Visit your My Account page to make your selections. Get the timely legal news and critical analysis you cannot afford to miss. Tailored just for you. In your inbox. Every day.

Copyright © 2020 ALM Media Properties, LLC. All Rights Reserved.